

PROPOSED DIRECTORS SENZAGEN AGM 2023



CARL BORREBAECK

Chairman since 2015, director since February 2010.
Born in 1948

Education and experience:

Professor of immunotechnology, DSc major in molecular immunology, MSc in chemical engineering, MSc in life science.

Carl Borrebaeck is a professor at the Department of Immunotechnology and program director of the CREATE translational cancer research center at Lund University. He is an entrepreneur and founded SenzaGen AB and several other life science companies, including Immunovia AB and Biolnvent International AB. He is also a founding mentor for the Nordic Mentor Network for Entrepreneurship (NOME), a member of the Royal Swedish Academy of Engineering Sciences (IVA) and former vice-chancellor at Lund University. Carl has won a number of awards for his entrepreneurship and groundbreaking research, including AkzoNobel's Science Prize in 2009 and the Biotech Builder Award in 2017.

Other significant appointments:

Board chairman of Immunovia AB, PainDrainer AB and CB Ocean Capital AB. Board director at Scandion A/S.

Shareholding:

1,698,571 shares (privately and through related parties).

Independence:

Not independent of major shareholders but independent of the Company and Management.



ANKI MALMBORG HAGER

Director since 2019.
Born in 1965.

Education and experience:

PhD in immunotechnology, MSc in chemical engineering, Pharma MBA.

Anki Malmberg Hager has extensive experience from starting life science companies originating from Lund university research. Anki served as CEO of SenzaGen from 2014 to 2019. Her past experience includes CEO of PainDrainer AB, Cantargia AB, XImmune AB and Diaprost AB, and before that, Investment Director at LU Bioscience AB and VP Business Development at Alligator Bioscience AB.

Other significant appointments:

Board director at Avena Partners AB, Colzyx AB and NanoEcho AB.

Shareholding:

383,000 shares.

Independence:

Not independent of the Company and Management. Independent of major shareholders.

Shareholdings at 11 March 2022

**IAN KIMBER**

Director since 2015.
Born in 1950.

Education and experience:

Emeritus professor of toxicology, PhD and MSc in immunology, BSc in biology.

Ian Kimber serves as Emeritus Professor of Toxicology at the University of Manchester. He has extensive experience from academia, the pharmaceutical, biopharmaceutical and agrochemical industries, and as an independent consultant. Ian has won several awards for his distinguished scientific work and received the OBE in the Queen's Birthday Honours List in 2011. He serves on many expert committees and scientific advisory groups in the UK and internationally.

Other significant appointments:

Emeritus Professor of Toxicology at the University of Manchester.

Shareholding:

1,500 shares.

Independence:

Independent of the Company, Management and major shareholders.

**PAULA ZEILON**

Director since 2020.
Born in 1962.

Education and experience:

MSc in chemical engineering and business administration

Paula Zeilon has 30 years of management experience from the life science industry including a consulting business in the field of business development and management focusing on the commercialization of new products on international markets. Her past experience includes CEO of Life Science Foresight Institute, CEO of Alligator Biosciences AB, Director Marketing at Dako A/S, Director Marketing at Biotage AB, and management positions with Pharmacia Biotech (now Cytiva).

Other significant appointments:

None.

Shareholding:

6,000 shares. 10,000 stock options.

Independence:

Independent of the Company, Management and major shareholders.

**PAUL YIANNI**

Director since 2020.
Born in 1959.

Education and experience:

PhD in chemistry.

Paul Yianni runs his own consulting business with a focus on business development, strategy and business coaching. Paul has over 30 years of management experience from the chemicals industry, and he has broad international experience from various technical and commercial functions, including at Dow Corning and Shell Chemicals. His previous positions include CEO of Spolchemie in Czechia and head of M&A at DIC Europe in Germany.

Other significant appointments:

None.

Shareholding:

30,000 shares. 15,000 stock options.

Independence:

Independent of the Company, Management and major shareholders.